Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Category: Pharma Industry
The federal government has agreed to temporarily delay any enforcement action against five health systems for their refusal to comply [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical giant Sanofi has intensified its legal battle seeking the release of extensive 340B contract pharmacy records after announcing plans [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B program continues to draw attention in conservative media outlets, with one recently published opinion piece calling for preserving [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical giant Bristol-Myers Squibb (BMS) sued the federal government late Tuesday to establish a 340B rebate model, joining at least [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Provider groups have strongly denounced Sanofi’s new 340B rebate model for hospitals and health centers as a costly and harmful [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three large hospital systems are asking a federal court to immediately block the government from removing them from the 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Breaking News
Wall Street Journal Reports Sanofi Will Become Third Drugmaker to Push for Controversial 340B Rebate
French pharmaceutical giant Sanofi reportedly plans to announce a 340B rebate model for hospitals today, making it the third drugmaker [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Katheryne Richardson, a former senior global pricing strategist at Bristol-Myers Squibb (BMS) and longtime vice president of Apexus, this week [...] …